Additionally, we preliminarily investigated the relationship between ENTPD8 expression and survival after immunotherapy in patients with pan-cancer (including bladder cancer, esophageal cancer, glioblastoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer, etc.). Here, ENTPD8 is linked to cancer.